169 related articles for article (PubMed ID: 34881851)
1. Theragnostic radionuclides: a clinical perspective.
Koziorowski J; Ballinger J
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):306-314. PubMed ID: 34881851
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Nuclear Medicine and Cancer Theragnostics: Basic Concepts.
Zoi V; Giannakopoulou M; Alexiou GA; Bouziotis P; Thalasselis S; Tzakos AG; Fotopoulos A; Papadopoulos AN; Kyritsis AP; Sioka C
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835806
[TBL] [Abstract][Full Text] [Related]
4. The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years.
Balma M; Liberini V; Buschiazzo A; Racca M; Rizzo A; Nicolotti DG; Laudicella R; Quartuccio N; Longo M; Perlo G; Terreno E; Abgral R; William Huellner M; Papaleo A; Deandreis D
Curr Med Imaging; 2023; 19(8):817-831. PubMed ID: 36797602
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
6. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
7. Side effects of theragnostic agents currently employed in clinical practice.
Rizzo A; Annunziata S; Salvatori M
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):315-326. PubMed ID: 34881848
[TBL] [Abstract][Full Text] [Related]
8. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
10. Economics of New Molecular Targeted Personalized Radiopharmaceuticals.
Cutler CS
Semin Nucl Med; 2019 Sep; 49(5):450-457. PubMed ID: 31470937
[TBL] [Abstract][Full Text] [Related]
11. Theranostic radiopharmaceuticals: established agents in current use.
Ballinger JR
Br J Radiol; 2018 Nov; 91(1091):20170969. PubMed ID: 29474096
[TBL] [Abstract][Full Text] [Related]
12. Molecular Imaging and Therapy for Neuroendocrine Tumors.
Desai H; Borges-Neto S; Wong TZ
Curr Treat Options Oncol; 2019 Aug; 20(10):78. PubMed ID: 31468190
[TBL] [Abstract][Full Text] [Related]
13. An international multi-center investigation on the accuracy of radionuclide calibrators in nuclear medicine theragnostics.
Saldarriaga Vargas C; Bauwens M; Pooters INA; Pommé S; Peters SMB; Segbers M; Jentzen W; Vogg A; van Velden FHP; Meyer Viol SL; Gotthardt M; Mottaghy FM; Wildberger JE; Covens P; Wierts R
EJNMMI Phys; 2020 Nov; 7(1):69. PubMed ID: 33226485
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
15. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
17. Theragnostics before we found its name.
Modoni S; Frangos S; Iakovou I; Boero M; Mansi L
Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):299-305. PubMed ID: 35133096
[TBL] [Abstract][Full Text] [Related]
18. From the Magic Bullet to Theragnostics: Certitudes and Hypotheses, Trying to Optimize the Somatostatin Model.
Di Stasio GD; Buonomano P; Travaini LL; Grana CM; Mansi L
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298688
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic radiopharmaceuticals.
Ercan MT; Caglar M
Curr Pharm Des; 2000 Jul; 6(11):1085-121. PubMed ID: 10903384
[TBL] [Abstract][Full Text] [Related]
20. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
